ALTERNATING WEEKLY TEMOZOLOMIDE AS INITIAL TREATMENT FOR PROGRESSIVE LOW-GRADE OLIGODENDROGLIAL TUMORS: A PHASE II AINO (ITALIAN ASSOCIATION FOR NEURO-ONCOLOGY) STUDY

被引：0
|
作者：
Soffietti, Riccardo [1 ]
Roda, Roberta [1 ]
Trevisan, Elisa [1 ]
Laguzzi, Elena [1 ]
Picco, Elisabetta [1 ]
Guarneri, Dainele [1 ]
Caroli, Manuela [2 ]
Crippa, Flavio [3 ]
机构：
[1] Univ Turin, Turin, Italy
[2] Univ Milan, Milan, Italy
[3] Ist Nazl Tumori, I-20133 Milan, Italy
来源：
NEURO-ONCOLOGY | 2008年 / 10卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：838 / 838
页数：1
相关论文
共 50 条
  • [1] PROTRACTED LOW DOSE TEMOZOLOMIDE (TMZ) AS INITIAL TREATMENT FOR PROGRESSIVE LOW-GRADE OLIGODENDROGLIAL TUMORS: A PHASE II AINO (ITALIAN ASSOCIATION FOR NEURO-ONCOLOGY) STUDY
    Trevisan, E.
    Laguzzi, E.
    Guarneri, D.
    Bomprezzi, C.
    Caroli, M.
    Leoncini, B.
    Soffietti, R.
    Ruda, R.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1069 - 1069
  • [2] Phase II trial of dose-dense temozolomide as initial treatment for progressive low-grade oligodendroglial tumors: A multicentric study of the Italian Association of Neuro-Oncology (AINO)
    Ruda, Roberta
    Bertero, Luca
    Trevisan, Elisa
    Pace, Andrea
    Carapella, Carmine Maria
    Dealis, Cristina
    Caroli, Manuela
    Faedi, Marina
    Bomprezzi, Chiara
    Soffietti, Riccardo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] DOSE-DENSE TEMOZOLOMIDE AS INITIAL TREATMENT FOR PROGRESSIVE LOW GRADE OLIGODENDROGLIAL TUMORS: A MULTICENTER PHASE II STUDY OF THE AINO (ITALIAN ASSOCIATION OF NEURO-ONCOLOGY)
    Ruda, R.
    Bertero, L.
    Trevisan, E.
    Pace, A.
    Carapella, C.
    Dealis, C.
    Caroli, M.
    Faedi, M.
    Bomprezzi, C.
    Soffietti, R.
    NEURO-ONCOLOGY, 2012, 14 : 11 - 11
  • [4] DOSE-DENSE TEMOZOLOMIDE AS INITIAL TREATMENT FOR PROGRESSIVE LOW-GRADE OLIGODENDROGLIAL TUMORS: A PHASE II STUDY OF THE ITALIAN ASSOCIATION OF NEURO-ONCOLOGY
    Ruda, Roberta
    Bertero, Luca
    Bosa, Chiara
    Trevisan, Elisa
    Pace, Andrea
    Carapella, Carmine
    Dealis, Cristina
    Caroli, Manuela
    Faedi, Marina
    Bomprezzi, Chiara
    NEURO-ONCOLOGY, 2012, 14 : 71 - 71
  • [5] TEMOZOLOMIDE (TMZ) 1 WEEK ON/1 WEEK OFF AS INITIAL TREATMENT FOR HIGH RISK LOW GRADE OLIGODENDROGLIAL TUMORS: A PHASE II AINO (ITALIAN ASSOCIATION FOR NEURO-ONCOLOGY) STUDY
    Pellerino, A.
    Franchino, F.
    Pace, A.
    Carapella, C.
    Dealis, C.
    Caroli, M.
    Faedi, M.
    Bomprezzi, C.
    Ruda, R.
    Soffietti, R.
    NEURO-ONCOLOGY, 2017, 19 : 21 - 21
  • [6] A phase II trial of temozolomide (TMZ) 1 week on/1 week off as initial treatment for high risk low grade oligodendroglial tumors: An AINO (Italian Association for Neuro-Oncology) study.
    Ruda, Roberta
    Pellerino, Alessia
    Franchino, Federica
    Pace, Andrea
    Carapella, Carmine Maria
    Dealis, Cristina
    Caroli, Manuela
    Faedi, Marina
    Bomprezzi, Chiara
    Soffietti, Riccardo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] DOSE DENSE TEMOZOLOMIDE (TMZ) AS INITIAL TREATMENT FOR HIGH-RISK OLIGODENDROGLIAL TUMORS: LONG-TERM RESULTS OF A PHASE II AINO (ITALIAN ASSOCIATION FOR NEURO-ONCOLOGY) STUDY
    Soffietti, Riccardo
    Pellerino, Alessia
    Pace, Andrea
    Carapella, Carmine
    Dealis, Cristina
    Caroli, Manuela
    Faedi, Marina
    Bello, Lorenzo
    Ruda, Roberta
    NEURO-ONCOLOGY, 2017, 19 : 2 - 2
  • [8] Treatment of gliomatosis cerebri with temozolomide: A retrospective study of the AINO (Italian Association for Neuro-Oncology)
    Soffietti, R.
    Ruda, R.
    Laguzzi, E.
    Buttolo, L.
    Pace, A.
    Carapella, C.
    Riva, M.
    Salvati, M.
    Silvani, A.
    Caroli, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Temozolomide (TMZ) 1 week on/1 week off as initial treatment for progressive low grade oligodendroglial tumors: A phase II AINO study
    Soffietti, R.
    Ruda, R.
    Trevisan, E.
    Laguzzi, E.
    Guarneri, D.
    Bomprezzi, C.
    Caroli, M.
    Leoncini, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Initial temozolomide for high-risk low-grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis of the efficacy within molecular subgroups of WHO 2016
    Franchino, F.
    Pellerino, A.
    Bruno, F.
    Bertero, L.
    Soffietti, R.
    Ruda, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 389 - 389
12345